The Exact Sciences [EXAS] stock price has stalled and entered a downward trend since the start of the year. The stock is down 18.4% year-to-date at $108.15 at the close on 17 September and is also down 32.2% from an all-time high of $159.54 on 25 January.
However, there are signs of a bullish movement ahead. In the past month, the Exact Sciences stock price has gained 15.6% and has found a support level at the $90 mark. To put this performance into context, the ever-popular ARK Genomic Revolution ETF [ARKG], which has the Exact Sciences stock as its second-biggest holding with a weighting of 5.29%, has a one-month return of 13.2%. Meanwhile, the S&P 500 Healthcare index has a negative month-to-date return of 1.7%.
If the Exact Sciences stock price were to fall below the $90 level, then the downward trend could continue. But share price analysis indicates that its resistance levels are between $110 and $120. And there’s good reason to believe that the Exact Sciences stock price could break past these levels in the near term.
Team expansion set to drive up colon cancer testing demand
Exact Sciences uses applied genomics to develop effective screening technologies for use in the detection of cancer, including an at-home testing kit for colon cancer, Cologuard, launched in 2014.
The company’s long-term goal has been to capture 40% of the US colorectal screening market.
In 2018, Exact Sciences signed a nationwide agreement with Pfizer [PFE], under which the pharmaceutical giant would help to market Cologuard and increase adoption of the testing kit until 2022.
A filing with the US Securities and Exchange Commission on 15 September this year showed Exact Sciences had hired 400 new sales representatives, doubling the size of its primary sales team to more than 850 employees. Most of the new hires are former Pfizer sales representatives.
Analysts have responded positively to the news. Canaccord Genuity analyst Kyle Mikson wrote in a note to clients seen by GenomeWeb that while the new headcount will add some incremental expenses, the expansion of the sales team “will be a net positive over time”. “The new reps could contribute to Exact’s other screening areas outside Cologuard,” Mikson added.
The move was described by William Blair analyst Brian Weinstein as “a no-brainer” because it “should drive faster uptake of Cologuard”.
High CAPEX but strong revenue growth
Exact Sciences spent $195m on sales and marketing in the three months to the end of June, as well as $106m on research and development (R&D). According to CSIMarket data, the year-on-year increase for capital expenditure was 177.6% compared with a medical laboratories industry average of a 39% decrease.
Amid the high spending, revenue grew by 61.7% year-on-year to $435m. This was far better than the medical laboratories industry average of 36.7% for the most recent quarter. Exact Science’s five-year average growth rate is 106.8% versus an industry growth rate of 23.3%.
Exact Sciences' Q2 revenue - a 61.7% YoY rise
The superior revenue growth rate is supported by a healthy gross margin rate of 73.8% in the second quarter of 2021 versus an industry average of 42.8%. The five-year average gross margin rates are 70.1% and 43.5%, respectively.
For diagnostics and medical testing companies like Exact Sciences, the gross margin is typically an important indicator for how much more can be reinvested into future R&D.
In the first half of 2021, Exact Sciences brought in $835m in total while spending more than $1bn.
While this may sound alarming, ongoing investment and innovation in marketing and R&D should continue to drive high revenue growth and allow Exact Sciences to fend off rivals in what is becoming a competitively fierce cancer testing market as well as capture a greater market share.
With Cologuard, Exact Sciences is well-positioned to be a market leader in colon cancer testing in the years ahead.
Bullish consensus sentiment for Exact Sciences stock
The Exact Sciences stock currently has 16 analyst ratings, according to MarketBeat data, of which one is a strong buy, 12 buys and three hold ratings. The targets assigned for the Exact Sciences stock price are between $120 and $180, with a consensus of $151.06, which implies an upside of 39.7% from the 17 September closing price. This is only slightly down from the $153.71 consensus three months ago, indicating that the positive sentiment around Exact Sciences has remained largely steady.
Disclaimer Past performance is not a reliable indicator of future results.
CMC Markets is an execution-only service provider. The material (whether or not it states any opinions) is for general information purposes only, and does not take into account your personal circumstances or objectives. Nothing in this material is (or should be considered to be) financial, investment or other advice on which reliance should be placed. No opinion given in the material constitutes a recommendation by CMC Markets or the author that any particular investment, security, transaction or investment strategy is suitable for any specific person.
The material has not been prepared in accordance with legal requirements designed to promote the independence of investment research. Although we are not specifically prevented from dealing before providing this material, we do not seek to take advantage of the material prior to its dissemination.
CMC Markets does not endorse or offer opinion on the trading strategies used by the author. Their trading strategies do not guarantee any return and CMC Markets shall not be held responsible for any loss that you may incur, either directly or indirectly, arising from any investment based on any information contained herein.
*Tax treatment depends on individual circumstances and can change or may differ in a jurisdiction other than the UK.